This week, mitochondrial disease is in focus during Mitochondrial Disease Week, highlighting a condition that, despite its often severe impact, remains relatively unknown. While research has progressed, there are still no approved treatments. Swedish biotech Abliva is at the forefront of changing this, with its phase II study of drug candidate KL1333 recently reaching a significant milestone.
Read the article about Abliva at biostock.se:
https://www.biostock.se/en/2024/09/abliva-leads-the-fight-against-mitochondrial-disease
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en/
